Vés al contingut

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01)

Obert
  • Codi protocol: D9802C00001
  • Codi EudraCT: 2023-508276-11
  • Grup de recerca: Recerca Biomèdica en Tumors de l'Aparell Digestiu
  • Servei: Oncologia
  • Investigador/a principal:  Acosta Eyzaguirre, Daniel
  • Malaltia: Tumors
  • Fase: Fase III
  • Estat: Reclutant voluntaris